1. Home
  2. ENTA vs BLND Comparison

ENTA vs BLND Comparison

Compare ENTA & BLND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

HOLD

Current Price

$12.58

Market Cap

374.6M

Sector

Health Care

ML Signal

HOLD

Logo Blend Labs Inc.

BLND

Blend Labs Inc.

HOLD

Current Price

$1.74

Market Cap

418.2M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENTA
BLND
Founded
1995
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
374.6M
418.2M
IPO Year
2012
2021

Fundamental Metrics

Financial Performance
Metric
ENTA
BLND
Price
$12.58
$1.74
Analyst Decision
Strong Buy
Buy
Analyst Count
5
6
Target Price
$20.40
$4.13
AVG Volume (30 Days)
147.1K
3.9M
Earning Date
05-11-2026
03-10-2026
Dividend Yield
N/A
N/A
EPS Growth
29.93
58.33
EPS
N/A
N/A
Revenue
$102,814,000.00
$123,585,000.00
Revenue This Year
$7.76
$16.90
Revenue Next Year
N/A
$15.83
P/E Ratio
N/A
N/A
Revenue Growth
16.48
N/A
52 Week Low
$4.09
$1.44
52 Week High
$17.15
$4.49

Technical Indicators

Market Signals
Indicator
ENTA
BLND
Relative Strength Index (RSI) 40.86 48.96
Support Level $12.09 $1.51
Resistance Level $15.52 $1.94
Average True Range (ATR) 0.65 0.16
MACD -0.16 0.04
Stochastic Oscillator 14.80 59.00

Price Performance

Historical Comparison
ENTA
BLND

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

About BLND Blend Labs Inc.

Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segments are; Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience, and the Title segment enables customers to streamline the title, settlement, and closing process at scale for mortgages, home equity lines of credit, and home equity loans. The majority of the revenue for the company is generated from the Blend Platform segment.

Share on Social Networks: